SK169699A3 - Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the treatment of cancer - Google Patents

Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the treatment of cancer Download PDF

Info

Publication number
SK169699A3
SK169699A3 SK1696-99A SK169699A SK169699A3 SK 169699 A3 SK169699 A3 SK 169699A3 SK 169699 A SK169699 A SK 169699A SK 169699 A3 SK169699 A3 SK 169699A3
Authority
SK
Slovakia
Prior art keywords
alkyl
phenyl
coa reductase
inhibitor
hmg coa
Prior art date
Application number
SK1696-99A
Other languages
English (en)
Slovak (sk)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SK169699A3 publication Critical patent/SK169699A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1696-99A 1997-06-16 1998-06-05 Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the treatment of cancer SK169699A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16
PCT/IB1998/000881 WO1998057633A1 (en) 1997-06-16 1998-06-05 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
SK169699A3 true SK169699A3 (en) 2000-06-12

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1696-99A SK169699A3 (en) 1997-06-16 1998-06-05 Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the treatment of cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (pt)
JP (1) JP3713051B2 (pt)
KR (1) KR100392573B1 (pt)
CN (1) CN1259868A (pt)
AP (1) AP9801261A0 (pt)
AR (1) AR013090A1 (pt)
AT (1) ATE235905T1 (pt)
BG (1) BG103946A (pt)
BR (1) BR9810616A (pt)
CA (1) CA2294399C (pt)
CO (1) CO4950607A1 (pt)
DE (1) DE69812933T2 (pt)
DK (1) DK0986387T3 (pt)
DZ (1) DZ2518A1 (pt)
EA (1) EA199901043A1 (pt)
ES (1) ES2196559T3 (pt)
GT (1) GT199800081A (pt)
HN (1) HN1998000091A (pt)
HR (1) HRP980328B1 (pt)
HU (1) HUP0004624A3 (pt)
ID (1) ID23014A (pt)
IL (1) IL132765A0 (pt)
IS (1) IS5259A (pt)
MA (1) MA24569A1 (pt)
NO (1) NO996206L (pt)
NZ (1) NZ500662A (pt)
OA (1) OA11231A (pt)
PA (1) PA8453601A1 (pt)
PE (1) PE82899A1 (pt)
PL (1) PL337651A1 (pt)
PT (1) PT986387E (pt)
SK (1) SK169699A3 (pt)
TN (1) TNSN98088A1 (pt)
TR (1) TR199903074T2 (pt)
UA (1) UA57081C2 (pt)
WO (1) WO1998057633A1 (pt)
ZA (1) ZA985182B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911785A (pt) 1998-05-12 2001-04-03 Warner Lambert Co Combinações de farnesil transferase de proteìna e inibidores de redutase de hmg coa e seu uso para tratar câncer
WO2000016778A1 (en) * 1998-09-24 2000-03-30 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
OA11231A (en) 2003-05-26
PT986387E (pt) 2003-06-30
MA24569A1 (fr) 1998-12-31
EP0986387A1 (en) 2000-03-22
HRP980328B1 (en) 2002-06-30
KR100392573B1 (ko) 2003-07-23
EA199901043A1 (ru) 2000-06-26
DE69812933T2 (de) 2003-11-06
NO996206D0 (no) 1999-12-15
CA2294399C (en) 2004-03-16
HRP980328A2 (en) 1999-04-30
HN1998000091A (es) 1999-09-29
JP2000513031A (ja) 2000-10-03
AP9801261A0 (en) 1999-12-11
ZA985182B (en) 1999-12-17
DZ2518A1 (fr) 2003-02-01
PE82899A1 (es) 1999-08-26
AR013090A1 (es) 2000-12-13
IL132765A0 (en) 2001-03-19
HUP0004624A2 (hu) 2001-10-28
ID23014A (id) 1999-12-30
BR9810616A (pt) 2000-09-12
ATE235905T1 (de) 2003-04-15
HUP0004624A3 (en) 2002-11-28
ES2196559T3 (es) 2003-12-16
TNSN98088A1 (fr) 2005-03-15
CN1259868A (zh) 2000-07-12
JP3713051B2 (ja) 2005-11-02
CA2294399A1 (en) 1998-12-23
WO1998057633A1 (en) 1998-12-23
AU7445998A (en) 1999-01-04
UA57081C2 (uk) 2003-06-16
GT199800081A (es) 1999-12-07
DE69812933D1 (de) 2003-05-08
AU724676B2 (en) 2000-09-28
DK0986387T3 (da) 2003-07-14
BG103946A (bg) 2000-07-31
EP0986387B1 (en) 2003-04-02
NO996206L (no) 2000-02-15
KR20010013839A (ko) 2001-02-26
CO4950607A1 (es) 2000-09-01
IS5259A (is) 1999-11-19
PA8453601A1 (es) 2000-05-24
TR199903074T2 (xx) 2000-05-22
NZ500662A (en) 2001-10-26
PL337651A1 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
US6071935A (en) Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
KR100386229B1 (ko) 히드록시카르바졸화합물의평활근유주및증식의억제
US5574025A (en) Inhibitors of prenyl-protein transferases
AP1375A (en) Substituted imidazoles as TAFIa inhibitors.
SK169699A3 (en) Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the treatment of cancer
JP2002503249A (ja) 癌の治療方法
JP2000507590A (ja) ファルネシル―タンパク質トランスフェラーゼ阻害剤
KR20010078803A (ko) 제약 복합제제
EA005859B1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
JP2007063288A (ja) エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
WO1997001275A1 (en) Combinations of inhibitors of farnesyl-protein transferase
EP1097382B1 (en) Imidazoline receptor binding compounds
US6087349A (en) Method for blocking neoplastic transformation of cells induced by ras oncogenes
AU724676C (en) Farnesyl transferase inhibitors in combination with hmg CoA reductase inhibitors for the treatment of cancer
US6160015A (en) Compounds useful in the treatment of neurofibromatosis
US20050203163A1 (en) Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
CZ448699A3 (cs) Inhibitory farnesyltransferasy v kombinaci s inhibitory HMG CoA reduktasy pro léčení rakoviny
JP2000507584A (ja) ファルネシル―タンパク質転移酵素の阻害剤
US20020151563A1 (en) Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
MXPA99011798A (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
US6174903B1 (en) Imidazolidin-4-one derivatives useful as anticancer agents
WO2022261643A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
JP2001514011A (ja) 癌の治療方法
AU2004200272A1 (en) Imidazoline Receptor binding compounds